IL-6 is also a therapeutic target for many diseases, and the efficacy of anti-IL-6 receptor (IL-6R) Tocilizumab as a single therapy or in combination with anti-rheumatic drugs in the treatment of moderate to severe rheumatoid arthritis in adults has been demonstrated (19). Here, IL6R is linked to rheumatoid arthritis.